{
  "title": "M21-1, Part VIII, Subpart iv, Chapter 8, Section D - Other Temporary Total Evaluations",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177543/M21-1-Part-VIII-Subpart-iv-Chapter-8-Section-D-Other-Temporary-Total-Evaluations",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Section\nThis section contains the following topics:\nTopic\nTopic Name\n1\nDiagnostic Codes (DCs) That Provide for Definite Periods of Schedular Temporary Total Evaluation\n2\nExamples of Definite Periods of Schedular Temporary Total Evaluation\n3\nDCs That Provide for Indefinite Periods of Schedular Temporary Total Evaluation\n1\n.\nDCs That Provide for Definite Periods of Schedular Temporary Total Evaluation\nIntroduction\nThis topic contains information on DCs that provide for definite periods of schedular temporary total evaluation, including\ntemporary total evaluations under a DC for a defined period\nDCs providing for temporary total evaluations – relationship to 38 CFR 4.29 and 4.30\ndefinition of definite periods of schedular temporary total evaluation\nstaged rating of definite periods of schedular temporary total evaluation\ncontrol and assignment of definite periods of schedular temporary total evaluation\n, and\nreexamination after a definite period of schedular temporary total evaluation\n.\nChange Date\nAugust 2, 2023\nVIII.iv.8.D.1.a\n.\nTemporary Total Evaluations Under a DC for a Defined Period\nThe rating schedule prescribes temporary 100-percent evaluations under various diagnostic codes (DCs) for definite periods of time following treatment (including hospitalization), surgery, or certain significant disease manifestations.\nVIII.iv.8.D.1.b\n.\nDCs Providing for Temporary Total Evaluations – Relationship to 38 CFR 4.29 and 4.30\nEntitlement to a period of temporary total evaluation under a DC does not necessarily preclude entitlement under\n38 CFR 4.29\nor\n38 CFR 4.30\nand vice versa.\nSome DCs (for example, those covering implantation of joint prostheses,\n38 CFR 4.71a, DC 5051-5056\n) specifically provide that the period of temporary total compensation will commence after an initial award of a period of total disability under\n38 CFR 4.30\n.\nIn other cases the temporary total disability period specified by a DC can read as more limited than what could be potentially supported under\n38 CFR 4.29\nor\n38 CFR 4.30\n.  For example,\n38 CFR 4.104, DC 7018\nprovides for a 100-percent evaluation for one month following hospital discharge for implantation or re-implantation of a cardiac pacemaker.  Arguably, this might be a shorter period of time than could be paid if there was a prolonged hospitalization for complications of the procedure or a need for more than one month of convalescence based on severe post-surgical residuals.  In such cases, use the provision that is more favorable to the Veteran.\nConversely, the fact that a DC provides for a period of temporary total disability does not necessarily mean that disability compensation under\n38 CFR 4.29\nor\n38 CFR 4.30\nwould be appropriate.\nA DC might provide for a temporary total evaluation triggered by hospitalization but not necessarily hospitalization of a sufficient duration to qualify for a\n38 CFR 4.29\nevaluation or hospitalization for surgery or major joint immobilization to qualify for a\n38 CFR 4.30\nevaluation (for example,\n38 CFR 4.104, DC 7011\nprovides for a 100-percent evaluation for an indefinite period from the date of inpatient hospital admission for initial medical therapy for sustained ventricular arrhythmia).\nIn those cases where a period of schedular entitlement to a temporary total evaluation follows a hospitalization, it should begin on the first of the month following\na hospital discharge, if benefits under\n38 CFR 4.29\nwere awarded, or\ndiscontinuance of a one-month temporary 100-percent rating under\n38 CFR 4.30\n.\nReference\n:  For more information on assigning temporary total evaluations following receipt of a\nReport of Hospitalization\nat a Department of Veterans Affairs (VA) hospital, see\nM21-1, Part VIII, Subpart iv, 8.C\n.\nVIII.iv.8.D.1.c\n.\nDefinition: Definite Periods of Schedular Temporary Total Evaluation\nA temporary 100-percent evaluation falls into the category\ndefinite periods of schedular temporary total evaluation\nwhen the DC\nspecifies the period of time for which the total evaluation is permitted,\nand\nidentifies the subsequent evaluation following the defined period of temporary total disability.\nExamples\n:\nKnee replacement (\n38 CFR 4.71a, DC 5055\n) –\nfour months\nfollowing implantation of prosthesis (commencing after an initial award of a one-month total rating under\n38 CFR 4.30\n).\nMyocardial infarction (\n38 CFR 4.104, DC 7006\n) – during and for\nthree months\nfollowing myocardial infarction.\nIn both examples the period of total disability and subsequent evaluation can be addressed in the rating decision.\nVIII.iv.8.D.1.d\n.\nStaged Rating of Definite Periods of Schedular Temporary Total Evaluation\nDefinite periods of schedular temporary total evaluation and subsequent evaluations can be assigned prospectively (where total disability is still ongoing at the time of the rating) or retrospectively (when the period of total disability has already ended).  In either case, definite periods of schedular temporary total evaluation are assigned as essentially a staged rating.\nIn the rating assign\ntotal disability for the specific period allowed,\nand\nimmediately thereafter the\ngreater of\nthe disability evaluation (if any) that existed before the period of total disability (to include an evaluation protected under\n38 CFR 3.951(b)\n)\na minimum rating (if specified in the DC), or\nanother evaluation established by facts of record at the time of rating.\nWhen following this rule,\n38 CFR 3.105(e)\nwill not apply to the assignment of a disability evaluation less than 100 percent after the total disability period because there will never be a reduction in payments currently being made.\nImportant\n:\n38 CFR 3.105(e)\nwill\napply, however, where a\nsubsequent\n(further) reduction may be needed that will result in reduction in payments currently being made.  This will occur where, for example\nthe definite period of schedular temporary total evaluation is being assigned prospectively and a minimum evaluation specified under the DC is lower than the running evaluation that was in effect prior to the total disability period (see Example 2 in\nM21-1, Part VIII, Subpart iv, 8.D.2.b\n),\nor\nthe definite period of schedular temporary total evaluation is being assigned retrospectively, and the factual level of disability after the definite period of schedular temporary total evaluation supports a lower evaluation than the running evaluation in effect before the temporary total period (see Example 3 in\nM21-1, Part VIII, Subpart iv, 8.D.2.c\n).\nReference\n:  For more information on setting a future examination for a schedular period of temporary total evaluation, see\nM21-1, Part VIII, Subpart iv, 8.D.1.f\n.\nVIII.iv.8.D.1.e\n.\nControl and Assignment of Definite Period of Schedular Temporary Total Evaluation\nA definite temporary total evaluation period requires no future control.  If rated correctly, there is no potential for overpayment of the total disability period.  The rating that assigns the 100-percent evaluation also sets a subsequent evaluation to take effect after the specified period of total disability ends.\nReference\n:  For information on control of indefinite periods of schedular temporary total evaluation, see\nM21-1, Part VIII, Subpart iv, 8.D.3\n.\nVIII.iv.8.D.1.f\n.\nReexamination After a Definite Period of Schedular Temporary Total Evaluation\nWhen preparing a rating decision prospectively awarding a definite period of schedular temporary total evaluation and a subsequent evaluation as provided in\nM21-1, Part VIII, Subpart iv, 8.D.1.d\n, do not schedule a future examination before the end of the temporary total period.\nHowever, a future examination date may be entered in the Veterans Benefits Management System – Rating to ensure that the disability will be reexamined and reevaluated after the prescribed schedular temporary total evaluation period has expired.  These exams may be necessary to determine\nif a higher evaluation is warranted in those cases where a minimum evaluation specified in the DC was assigned after the definite period of schedular temporary total evaluation, or\nif reduction of the evaluation following the temporary total evaluation period is warranted (for example where\n38 CFR 3.105(e)\ndictates reassignment of the running evaluation in effect prior to the period of temporary total evaluation) except where the running evaluation is a minimum or protected evaluation.\nGenerally, when retrospectively awarding a period of temporary total disability, the level of disability after the end of the period of total disability (the current level of disability) will be known.  In such cases do not establish a future examination control except as provided in\n38 CFR 3.327(b)\nand\nM21-1, Part IV, Subpart ii, 1.A\n.\n2\n.\nExamples of Definite Periods of Schedular Temporary Total Evaluation\nIntroduction\nThis topic contains examples of definite periods of schedular temporary total evaluation, including\nexample 1: staged rating of definite period of schedular temporary total evaluation\nexample 2: staged rating of definite period of schedular temporary total evaluation\n, and\nexample 3: staged rating of definite period of schedular temporary total evaluation\n.\nChange Date\nJuly 29, 2021\nVIII.iv.8.D.2.a\n.\nExample 1: Staged Rating of Definite Period of Schedular Temporary Total Evaluation\nFacts\n:  The determination involves a prospective increased rating for a knee replacement under\n38 CFR 4.71a, DC 5055\n.  The knee replacement occurred three months before the date of rating.  The prior evaluation of the knee was 20 percent.  There are no other disabilities.\nResult\n:  In the rating decision\naward the increased evaluation of 100 percent, and\nschedule assignment of the minimum rating of 30 percent to take effect after the end of the total disability period.\nExplanation\n:\nThe minimum 30-percent evaluation is the greater when choosing between that evaluation and the running evaluation of 20 percent.  In a prospective evaluation there are not facts about the future condition of the disability to consider another level of disability.\n38 CFR 3.105(e)\ndoes not apply because at no point in time is the claimant being paid less than the running 20-percent rate.  The rating is staging up to the 100-percent rate and prospectively down to a rate greater than 20 percent.\nVIII.iv.8.D.2.b\n.\nExample 2: Staged Rating of Definite Period of Schedular Temporary Total Evaluation\nFacts\n:  The determination involves a prospective increased rating for a knee replacement under\n38 CFR 4.71a, DC 5055\n.  The knee replacement occurred three months before the date of rating.  The prior evaluation of the knee was 50 percent.  There are no other disabilities.\nResult\n:  In the rating decision\ngrant the increased evaluation of 100 percent, and\nschedule assignment of a 50-percent evaluation to take effect after the end of the total disability period.\nExplanation\n:\nThe 50-percent evaluation is the greater when choosing between the running evaluation and the minimum evaluation of 30 percent.  In a prospective evaluation there are not facts about the future condition of the disability to consider another level of disability higher than 30 percent.\n38 CFR 3.105(e)\ndoes not apply because at no point in time is the claimant being paid less than the running 50-percent rate.  The rating is staging up to the 100-percent rate and prospectively down to that rate.\nHowever,\nin the future\n, as or after the 50-percent evaluation goes into effect, facts may show that only the minimum 30-percent evaluation is warranted.  At\nthat point in time\nthe further reduction in evaluation would cause a reduction in the payments being made at that time (at the 50-percent rate) so\n38 CFR 3.105(e)\nwould apply.\nNote\n:  This example is to illustrate staging principles, but in fact patterns like this (a high joint evaluation followed by joint replacement and higher than the minimum evaluation after the temporary total period) strongly consider a future examination to the extent justified by\n38 CFR 3.327\nand as provided by\nM21-1, Part VIII, Subpart iv, 8.D.1.f\n.\nVIII.iv.8.D.2.c\n.\nExample 3: Staged Rating of Definite Period of Schedular Temporary Total Evaluation\nFacts\n:  The determination involves a retrospective increased rating for a knee replacement under\n38 CFR 4.71a, DC 5055\n.  The claim was received 11 months after the knee replacement.  A disability benefits questionnaire showed that the prosthetic was stable and the Veteran was asymptomatic.  The prior, running evaluation of the knee was 40 percent.  There are no other disabilities.\nResult\n:  In the rating decision\naward the increased evaluation of 100 percent\nassign a 40-percent evaluation to take effect after the end of the total disability period, and\npropose reduction to 30 percent.\nExplanation\n:\nThe 40-percent evaluation is the greater when choosing between running evaluation, the minimum evaluation of 30 percent, and the facts.\n38 CFR 3.105(e)\ndoes not apply to the decision to assign a 40-percent evaluation after the period of total disability because in doing so the claimant is never being paid less than the running 40-percent rate.  The rating is staging up to the 100-percent rate and prospectively down to that rate.\nHowever, the continuance of the 40-percent rate is contrary to the current facts.  The facts support only the minimum 30-percent evaluation and further reduction in evaluation would cause a reduction from the running 40 percent level.  Therefore,\n38 CFR 3.105(e)\nwould apply and further reduction must be proposed.\n3\n.\nDCs That Provide for Indefinite Periods of Schedular Temporary Total Evaluation\nIntroduction\nThis topic contains information on DCs that provide for indefinite periods of schedular temporary total evaluation, including\nindefinite periods of schedular temporary total evaluation under a DC\ndefinition of indefinite periods of schedular temporary total evaluation\nprospective ratings under indefinite periods of schedular temporary total evaluation and 38 CFR 3.105(e)\nretrospective evaluations of indefinite periods of schedular temporary total evaluation and 38 CFR 3.105(e)\ncancer evaluations\n, and\nan example of a staged cancer evaluation\n.\nChange Date\nAugust 3, 2020\nVIII.iv.8.D.3.a\n.\nIndefinite Periods of Schedular Temporary Total Evaluation Under a DC\nThe rating schedule prescribes temporary 100-percent evaluations under various DCs for indefinite periods of time following treatment (including hospitalization), surgery, or certain significant disease manifestations.\nReference\n:  For more information on the interrelationship between schedular temporary total evaluations under a DC generally and\n38 CFR 4.29\nor\n38 CFR 4.30\n, see\nM21-1, Part VIII, Subpart iv, 8.D.1.b\n.\nVIII.iv.8.D.3.b\n.\nDefinition: Indefinite Periods of Schedular Temporary Total Evaluation\nA temporary 100-percent evaluation falls into the category\nindefinite periods of schedular temporary total evaluation\nwhen\nthe 100-percent criteria refers to an “indefinite” period or does not specify the period for which the total evaluation is permitted,\nor\nthe end point for total disability is not known, therefore may not be set, at the time of rating.\nKey features of DC provisions providing for indefinite periods of schedular temporary total evaluation also include\nindication that current evidence of active disease or treatment will require a reexamination and reassessment of the disability level, and\na statement that reduction of the total disability is subject to the provisions of\n38 CFR 3.105(e)\n.\nExamples\n:\nA mandatory examination is conducted no sooner than one year following hospital discharge subsequent to kidney transplant surgery under\n38 CFR 4.115b, DC 7531\n.\nThe period that the total disability will run may be a year or it may be longer, and the subsequent evaluation is dependent upon reexamination.\nWhen the exam will be completed and what subsequent evaluation may be appropriate will not be known at the time of rating.\nAn examination is to be conducted under\n38 CFR 4.115b, DC 7528\nno sooner than six months following the point at which a malignant neoplasm of the genitourinary system becomes inactive and there is no further antineoplastic treatment or therapy.\nThe period of total disability is not limited.\nBased on the need for evidence of inactivity, end of treatment, and review examination, the end point for total disability will not be known and set at the time of rating.\nReference\n:  For more information on assigning temporary total evaluations following receipt of a\nReport of Hospitalization\nat a VA hospital, see\nM21-1, Part VIII, Subpart iv, 8.C\n.\nVIII.iv.8.D.3.c\n.\nProspective Ratings Under Indefinite Periods of Schedular Temporary Total Evaluation and 38 CFR 3.105(e)\n38 CFR 3.105(e)\napplies to reductions from the period of total disability specified in DCs providing for indefinite periods of schedular temporary total evaluation because these evaluations are most often awarded\nprospectively\n(total disability is still ongoing at the time of the rating).\nAt time of rating the decision maker will not know either one of the following:\nthe date that a future evaluation will replace the 100-percent rate, or\nthe level of evaluation that is appropriate to subsequently assign.\nTherefore, the 100-percent evaluation is assigned as an open or running evaluation and later assignment of a lower evaluation after the indefinite period of schedular temporary total evaluation can result in a reduction or discontinuance of compensation payments being made.\nWhen preparing a rating decision prospectively establishing a temporary total evaluation for an indefinite period\nenter the total disability from the effective date, and\nassign a date for a future examination only if appropriate under\nM21-1, Part IV, Subpart ii, 1.A\nand the facts of record.\nLater, when the period of total disability has ended, before assigning a lower evaluation\nensure that any examination report required by the DC is completed and considered, and\napply the provisions of\n38 CFR 3.105(e)\nwhen the rating will cause any reductions from the running total disability rate.\nReferences\n:  For more information on\nconsideration of\n38 CFR 3.105(e)\n, see\nM21-1, Part X, Subpart ii, 4.A\nretrospective evaluations under DCs providing for indefinite periods of schedular temporary total evaluation, see\nM21-1, Part VIII, Subpart iv, 8.D.3.d\n, and\nreducing staged ratings in original disability claims, see\nTatum v. Shinseki\n, 24 Vet.App. 139 (2010).\nVIII.iv.8.D.3.d\n.\nRetrospective Evaluations of Indefinite Periods of Schedular Temporary Total Evaluation and 38 CFR 3.105(e)\nIt is possible, in rare cases, that a temporary total evaluation under an indefinite period of schedular temporary total evaluation can be assigned retrospectively (when the period of total disability has already ended).\nThis can occur when a claim has a long duration or where the period of total disability was short.\nIn such cases the period of total disability and the subsequent disability level will be actually known at the time of rating.  Staging up to 100 percent and then down to the appropriate following level will not require application of the provisions of\n38 CFR 3.105(e)\nas long as there is not a reduction in compensation payments currently being made.\nImportant\n:  If the total evaluation is reduced as part of a staged rating in the award for the original claim for such disability, then the provisions of\n38 CFR 3.105(e)\ndo not apply.\nVIII.iv.8.D.3.e\n.\nCancer Evaluations\nAlmost all cancers are evaluated using the same analysis.  See the table below for a description.\nStage\nDescription\n1\nA 100-percent evaluation is assigned for active cancer. This rating is typically assigned prospectively and can run indefinitely. If permanence is not conceded, schedule a review examination based on the evidence of record to ascertain continued status of active cancer or treatment.\n2\nEvidence is submitted or obtained that there is no further surgical, x-ray, chemotherapy, or other qualifying antineoplastic treatment because the cancer is inactive.\n3\nWhen a cancer is being evaluated prospectively, such that the period of active symptoms is at or near the time of the analysis and associated decision making, VA schedules an examination\nno sooner than\nsix months after discontinuance of the treatment or evidence of the cessation of active disease to determine whether there has been local recurrence or metastasis.\nIn cases where the examination finds that the cancer is not active and/or does not require further treatment, the examination will also provide information for use in determining a rating based on residuals.\nNotes\n:\nTreatment records are insufficient to serve as the requirement for a VA examination.\nWhere VA records exist, check the most current records in Compensation and Pension Records Interchange before ordering the examination to ensure that the cancer is no longer active and that the Veteran has not received antineoplastic treatment for at least six months.\nFor guidance on evaluating cancer retrospectively, refer to the exception in Step 4.\n4\nVA takes rating action to reduce the total evaluation to an evaluation for residuals from an appropriate effective date based on the examination results and any other evidence of record.\nImportant\n:  Any change in evaluation shall be subject to the provisions of\n38 CFR 3.105(e)\n(requiring a proposed reduction, a 60-day opportunity to respond, and\nprospective reduction\nor discontinuance effective the last day of the month in which a 60-day period from the date of notice of the final rating action expires).\nException\n:  As the court held in\nTatum v. Shinseki\n, 24 Vet.App. 139 (2010),\n38 CFR 3.105(e)\nrequirements are not applicable when the reduction is part of a staged rating assigned in the initial evaluation of the disability.  In that circumstance, once examination results or other medical evidence adequate for rating purposes showing residuals of the cancer are received, the total evaluation can be staged down on a facts-found basis to a date as early as six months after discontinuance of treatment –\neven if that date was before the date of the examination, if needed,\nsubject to two important related principles:\nthe evidence must support the reduction on the date chosen, and\nthe facts-found date of reduction cannot take effect earlier than six months following cessation of treatment for the malignant neoplasm.\nReference\n:  For more information on scheduling review examinations, see\nM21-1, Part IV, Subpart ii, 1.A\nand\nB\n.\nVIII.iv.8.D.3.f\n.\nExample:  Staged Cancer Evaluation\nFacts\n:\nAn original claim for service connection for prostate cancer was received May 1, 2012.\nAt that time there is active cancer.\nA prostatectomy is performed on June 20, 2012.\nFollow-up evaluations indicated that no antineoplastic treatment was needed.\nA VA examination was conducted June 6, 2013.\nThe examination confirmed that cancer had not recurred or metastasized.\nExam findings were notable only for subjective reports of urinary frequency of daytime voiding interval between two and three hours.\nThe examiner reviewed treatment records of private urologist and oncologist and noted that the exam findings were consistent with findings from all private reports over the prior eight months (since October 2012).\nFor this scenario, all evidence is reviewed for the original rating for the claimed prostate cancer.\nResult\n:\nAward a 100-percent evaluation from the date of claim.\nThe reduced evaluation is warranted December 20, 2012, six months after cessation of treatment for a malignant neoplasm.\nExplanation\n:\nThe VA exam supports that the cancer did not recur at any time after June 20, 2012, and the disability shown since October 2012 was consistent with a 10-percent evaluation.\nHowever, October 2012 is not at least six months after the end of antineoplastic treatment.  The earliest date that the 100-percent evaluation can be staged down is December 20, 2012.\nThe effective day of payment for the 10-percent evaluation is January 1, 2013.  Such action is consistent with standard practices and eliminates technical issues regarding establishment of a payment period prior to the end of the month.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177542\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 8, Section C - Convalescent Ratings Under 38 CFR 4.30\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177542/M21-1-Part-VIII-Subpart-iv-Chapter-8-Section-C-Convalescent-Ratings-Under-38-CFR-430\">&lt;-- Previous Section</a> <a articleid=\"554400000177488\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 9, Section A - Claims Based on Participation in Special Operations Incidents\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177488/M21-1-Part-VIII-Subpart-iv-Chapter-9-Section-A-Claims-Based-on-Participation-in-Special-Operations-Incidents\">Next Section --&gt;</a></span></span></p><p class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Overview</strong></span></span></a></p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">In This Section</span></span></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">This section contains the following topics: </span></span></div> <div><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></div> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"height: 0px; width: 495px; border-spacing: 0px; border-collapse: revert;\" width=\"495\"> <tbody> <tr> <td style=\"width: 87px; padding: 0px;\"> <div style=\"text-align: center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>Topic</strong></span></span></div> </td> <td style=\"width: 333px; padding: 0px;\"> <div style=\"text-align: center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>Topic Name</strong></span></span></div> </td> </tr> <tr> <td style=\"width: 87px; padding: 0px;\"> <div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">1</span></span></div> </td> <td style=\"width: 333px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#1\" target=\"_self\">Diagnostic Codes (DCs) That Provide for Definite Periods of Schedular Temporary Total Evaluation</a></span></span></div> </td> </tr> <tr> <td style=\"width: 87px; padding: 0px;\"> <div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">2</span></span></div> </td> <td style=\"width: 333px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#2\" target=\"_self\">Examples of Definite Periods of Schedular Temporary Total Evaluation</a></span></span></div> </td> </tr> <tr> <td style=\"width: 87px; padding: 0px;\"> <div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">3</span></span></div> </td> <td style=\"width: 333px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#3\" target=\"_self\">DCs That Provide for Indefinite Periods of Schedular Temporary Total Evaluation<span style=\"display: none\"> </span><span style=\"display: none\"> </span></a></span></span></div> </td> </tr> </tbody> </table> <div></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div class=\"ng-scope\"><br/> <br/><br/> <span style=\"font-size: 16px\"><strong><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">1<a id=\"1\" name=\"1\">.</a>  DCs That Provide for Definite Periods of Schedular Temporary Total Evaluation</span></span></strong></span></div><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><p> <br/> </p><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information on DCs that provide for definite periods of schedular temporary total evaluation, including</span></span></span></div> <ul> <li> <div><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">temporary total evaluations under a DC for a defined period</span></span></span></a></div> </li> <li> <div><a href=\"#1b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">DCs providing for temporary total evaluations – relationship to 38 CFR 4.29 and 4.30</span></span></span></a></div> </li> <li> <div><a href=\"#1c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">definition of definite periods of schedular temporary total evaluation</span></span></span></a></div> </li> <li> <div><a href=\"#1d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">staged rating of definite periods of schedular temporary total evaluation</span></span></span></a></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1e\" target=\"_self\">control and assignment of definite periods of schedular temporary total evaluation</a>, and</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1f\" target=\"_self\">reexamination after a definite period of schedular temporary total evaluation</a>.</span></span></span></div> </li> </ul> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">August 2, 2023</span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.1.a<a id=\"1a\" name=\"1a\">.</a>  Temporary Total Evaluations Under a DC for a Defined Period</span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The rating schedule prescribes temporary 100-percent evaluations under various diagnostic codes (DCs) for definite periods of time following treatment (including hospitalization), surgery, or certain significant disease manifestations. </span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"height: 24px; width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.1.b<a id=\"1b\" name=\"1b\">.</a>  DCs Providing for Temporary Total Evaluations – Relationship to 38 CFR 4.29 and 4.30</span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"></td> <td style=\"height: 24px; width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Entitlement to a period of temporary total evaluation under a DC does not necessarily preclude entitlement under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_129&amp;rgn=div8\" target=\"_blank\">38 CFR 4.29</a> or <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_130&amp;rgn=div8\" target=\"_blank\">38 CFR 4.30</a> and vice versa.</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Some DCs (for example, those covering implantation of joint prostheses, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3d75649930f683e754ee2bb72720319a&amp;mc=true&amp;node=se38.1.4_171a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.71a, DC 5051-5056</a>) specifically provide that the period of temporary total compensation will commence after an initial award of a period of total disability under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_130&amp;rgn=div8\" target=\"_blank\">38 CFR 4.30</a>.</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">In other cases the temporary total disability period specified by a DC can read as more limited than what could be potentially supported under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_129&amp;rgn=div8\" target=\"_blank\">38 CFR 4.29</a> or <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_130&amp;rgn=div8\" target=\"_blank\">38 CFR 4.30</a>.  For example, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7018</a> provides for a 100-percent evaluation for one month following hospital discharge for implantation or re-implantation of a cardiac pacemaker.  Arguably, this might be a shorter period of time than could be paid if there was a prolonged hospitalization for complications of the procedure or a need for more than one month of convalescence based on severe post-surgical residuals.  In such cases, use the provision that is more favorable to the Veteran. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Conversely, the fact that a DC provides for a period of temporary total disability does not necessarily mean that disability compensation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_129&amp;rgn=div8\" target=\"_blank\">38 CFR 4.29</a> or <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_130&amp;rgn=div8\" target=\"_blank\">38 CFR 4.30</a> would be appropriate.</span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">A DC might provide for a temporary total evaluation triggered by hospitalization but not necessarily hospitalization of a sufficient duration to qualify for a <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_129&amp;rgn=div8\" target=\"_blank\">38 CFR 4.29</a> evaluation or hospitalization for surgery or major joint immobilization to qualify for a <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_130&amp;rgn=div8\" target=\"_blank\">38 CFR 4.30</a> evaluation (for example, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=e8efbac6c174a1f08121bc677943d397&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7011</a> provides for a 100-percent evaluation for an indefinite period from the date of inpatient hospital admission for initial medical therapy for sustained ventricular arrhythmia).</span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">In those cases where a period of schedular entitlement to a temporary total evaluation follows a hospitalization, it should begin on the first of the month following</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">a hospital discharge, if benefits under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=814b9180da916bc488138110ab478909&amp;node=se38.1.4_129&amp;rgn=div8\" target=\"_blank\">38 CFR 4.29</a> were awarded, or</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">discontinuance of a one-month temporary 100-percent rating under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=814b9180da916bc488138110ab478909&amp;node=se38.1.4_130&amp;rgn=div8\" target=\"_blank\">38 CFR 4.30</a>.</span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on assigning temporary total evaluations following receipt of a <em>Report of Hospitalization</em> at a Department of Veterans Affairs (VA) hospital, see <a articleid=\"554400000177542\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 8, Section C - Convalescent Ratings Under 38 CFR 4.30\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177542/M21-1-Part-VIII-Subpart-iv-Chapter-8-Section-C-Convalescent-Ratings-Under-38-CFR-430\">M21-1, Part VIII, Subpart iv, 8.C</a>.</span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.1.c<a id=\"1c\" name=\"1c\">.</a>  Definition: Definite Periods of Schedular Temporary Total Evaluation</span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">A temporary 100-percent evaluation falls into the category<strong><em> definite periods of schedular temporary total evaluation</em></strong> when the DC</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">specifies the period of time for which the total evaluation is permitted, <em>and</em></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">identifies the subsequent evaluation following the defined period of temporary total disability. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Examples</em></strong>:  </span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Knee replacement (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=e8efbac6c174a1f08121bc677943d397&amp;node=se38.1.4_171a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.71a, DC 5055</a>) – <em>four months</em> following implantation of prosthesis (commencing after an initial award of a one-month total rating under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_130&amp;rgn=div8\" target=\"_blank\">38 CFR 4.30</a>). </span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Myocardial infarction (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=e8efbac6c174a1f08121bc677943d397&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7006</a>) – during and for <em>three months</em> following myocardial infarction.  </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">In both examples the period of total disability and subsequent evaluation can be addressed in the rating decision.</span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.1.d<a id=\"1d\" name=\"1d\">.</a>  Staged Rating of Definite Periods of Schedular Temporary Total Evaluation</span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Definite periods of schedular temporary total evaluation and subsequent evaluations can be assigned prospectively (where total disability is still ongoing at the time of the rating) or retrospectively (when the period of total disability has already ended).  In either case, definite periods of schedular temporary total evaluation are assigned as essentially a staged rating.</span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">In the rating assign</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">total disability for the specific period allowed, <em>and</em></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">immediately thereafter the <em>greater of</em></span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">the disability evaluation (if any) that existed before the period of total disability (to include an evaluation protected under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=0492397295b1bf21b63311e89f43cb5c&amp;mc=true&amp;node=se38.1.3_1951&amp;rgn=div8\" target=\"_blank\">38 CFR 3.951(b)</a>)</span></span></span></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">a minimum rating (if specified in the DC), or</span></span></span></span></span></span></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">another evaluation established by facts of record at the time of rating.</span></span></div> </li> </ul> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">When following this rule, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> will not apply to the assignment of a disability evaluation less than 100 percent after the total disability period because there will never be a reduction in payments currently being made. </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Important</em></strong>:  <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> <em>will</em> apply, however, where a <em>subsequent</em> (further) reduction may be needed that will result in reduction in payments currently being made.  This will occur where, for example</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">the definite period of schedular temporary total evaluation is being assigned prospectively and a minimum evaluation specified under the DC is lower than the running evaluation that was in effect prior to the total disability period (see Example 2 in <a href=\"#2b\" target=\"_self\">M21-1, Part VIII, Subpart iv, 8.D.2.b</a>), <em>or</em></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">the definite period of schedular temporary total evaluation is being assigned retrospectively, and the factual level of disability after the definite period of schedular temporary total evaluation supports a lower evaluation than the running evaluation in effect before the temporary total period (see Example 3 in <a href=\"#2c\" target=\"_self\">M21-1, Part VIII, Subpart iv, 8.D.2.c</a>). </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on setting a future examination for a schedular period of temporary total evaluation, see <a href=\"#1f\" target=\"_self\">M21-1, Part VIII, Subpart iv, 8.D.1.f</a>.</span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.1.e<a id=\"1e\" name=\"1e\">.</a>  Control and Assignment of Definite Period of Schedular Temporary Total Evaluation</span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">A definite temporary total evaluation period requires no future control.  If rated correctly, there is no potential for overpayment of the total disability period.  The rating that assigns the 100-percent evaluation also sets a subsequent evaluation to take effect after the specified period of total disability ends.</span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For information on control of indefinite periods of schedular temporary total evaluation, see <a href=\"#3\" target=\"_self\">M21-1, Part VIII, Subpart iv, 8.D.3</a>.</span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.1.f<a id=\"1f\" name=\"1f\">.</a>  Reexamination After a Definite Period of Schedular Temporary Total Evaluation</span></strong></span></span></span></span></span></strong></h3> <div><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></span></span></span></strong></div> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">When preparing a rating decision prospectively awarding a definite period of schedular temporary total evaluation and a subsequent evaluation as provided in <a href=\"#1d\" target=\"_self\">M21-1, Part VIII, Subpart iv, 8.D.1.d</a>, do not schedule a future examination before the end of the temporary total period. </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">However, a future examination date may be entered in the Veterans Benefits Management System – Rating to ensure that the disability will be reexamined and reevaluated after the prescribed schedular temporary total evaluation period has expired.  These exams may be necessary to determine</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">if a higher evaluation is warranted in those cases where a minimum evaluation specified in the DC was assigned after the definite period of schedular temporary total evaluation, or</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">if reduction of the evaluation following the temporary total evaluation period is warranted (for example where <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> dictates reassignment of the running evaluation in effect prior to the period of temporary total evaluation) except where the running evaluation is a minimum or protected evaluation.  </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Generally, when retrospectively awarding a period of temporary total disability, the level of disability after the end of the period of total disability (the current level of disability) will be known.  In such cases do not establish a future examination control except as provided in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=9aedef38b71a775fb25e47eb84124eaa&amp;mc=true&amp;node=se38.1.3_1327&amp;rgn=div8\" target=\"_blank\">38 CFR 3.327(b)</a> and <a articleid=\"554400000014321\" articlename=\"M21-1, Part IV, Subpart ii, Chapter 1, Section A - Determining the Need for Review Examinations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014321/M21-1-Part-IV-Subpart-ii-Chapter-1-Section-A-Determining-the-Need-for-Review-Examinations\">M21-1, Part IV, Subpart ii, 1.A</a>.</span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><div class=\"ng-scope\"><br/> <br/><br/> <span style=\"font-size: 16px\"><strong><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">2<a id=\"2\" name=\"2\">.</a>  Examples of Definite Periods of Schedular Temporary Total Evaluation</span></span></strong></span></div><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><p> <br/> </p><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains examples of definite periods of schedular temporary total evaluation, including </span></span></span></div> <ul> <li> <div><a href=\"#2a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">example 1: staged rating of definite period of schedular temporary total evaluation</span></span></span></a></div> </li> <li> <div><a href=\"#2b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">example 2: staged rating of definite period of schedular temporary total evaluation</span></span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">, and</span></span></span></div> </li> <li> <div><a href=\"#2c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">example 3: staged rating of definite period of schedular temporary total evaluation</span></span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">.</span></span></span></div> </li> </ul> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">July 29, 2021</span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.2.a<a id=\"2a\" name=\"2a\">.</a>  Example 1: Staged Rating of Definite Period of Schedular Temporary Total Evaluation</span></strong></span></span></span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Facts</em></strong>:  The determination involves a prospective increased rating for a knee replacement under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3d75649930f683e754ee2bb72720319a&amp;mc=true&amp;node=se38.1.4_171a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.71a, DC 5055</a>.  The knee replacement occurred three months before the date of rating.  The prior evaluation of the knee was 20 percent.  There are no other disabilities.</span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:  In the rating decision</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">award the increased evaluation of 100 percent, and </span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">schedule assignment of the minimum rating of 30 percent to take effect after the end of the total disability period. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Explanation</em></strong>:</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The minimum 30-percent evaluation is the greater when choosing between that evaluation and the running evaluation of 20 percent.  In a prospective evaluation there are not facts about the future condition of the disability to consider another level of disability.</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> does not apply because at no point in time is the claimant being paid less than the running 20-percent rate.  The rating is staging up to the 100-percent rate and prospectively down to a rate greater than 20 percent.</span></span></span></div> </li> </ul> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.2.b<a id=\"2b\" name=\"2b\">.</a>  Example 2: Staged Rating of Definite Period of Schedular Temporary Total Evaluation</span></strong></span></span></span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Facts</em></strong>:  The determination involves a prospective increased rating for a knee replacement under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3d75649930f683e754ee2bb72720319a&amp;mc=true&amp;node=se38.1.4_171a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.71a, DC 5055</a>.  The knee replacement occurred three months before the date of rating.  The prior evaluation of the knee was 50 percent.  There are no other disabilities.</span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:  In the rating decision</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">grant the increased evaluation of 100 percent, and</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">schedule assignment of a 50-percent evaluation to take effect after the end of the total disability period. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Explanation</em></strong>: </span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The 50-percent evaluation is the greater when choosing between the running evaluation and the minimum evaluation of 30 percent.  In a prospective evaluation there are not facts about the future condition of the disability to consider another level of disability higher than 30 percent.</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> does not apply because at no point in time is the claimant being paid less than the running 50-percent rate.  The rating is staging up to the 100-percent rate and prospectively down to that rate. </span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">However, <em>in the future</em>, as or after the 50-percent evaluation goes into effect, facts may show that only the minimum 30-percent evaluation is warranted.  At <em>that point in time</em> the further reduction in evaluation would cause a reduction in the payments being made at that time (at the 50-percent rate) so <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> would apply. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  This example is to illustrate staging principles, but in fact patterns like this (a high joint evaluation followed by joint replacement and higher than the minimum evaluation after the temporary total period) strongly consider a future examination to the extent justified by <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=6df760a2ba821e0c11058145aee4e2fa&amp;mc=true&amp;node=se38.1.3_1327&amp;rgn=div8\" target=\"_blank\">38 CFR 3.327</a> and as provided by <a href=\"#1f\" target=\"_self\">M21-1, Part VIII, Subpart iv, 8.D.1.f</a>.</span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.2.c<a id=\"2c\" name=\"2c\">.</a>  Example 3: Staged Rating of Definite Period of Schedular Temporary Total Evaluation</span></strong></span></span></span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Facts</em></strong>:  The determination involves a retrospective increased rating for a knee replacement under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3d75649930f683e754ee2bb72720319a&amp;mc=true&amp;node=se38.1.4_171a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.71a, DC 5055</a>.  The claim was received 11 months after the knee replacement.  A disability benefits questionnaire showed that the prosthetic was stable and the Veteran was asymptomatic.  The prior, running evaluation of the knee was 40 percent.  There are no other disabilities.</span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:  In the rating decision</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">award the increased evaluation of 100 percent </span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">assign a 40-percent evaluation to take effect after the end of the total disability period, and</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">propose reduction to 30 percent. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Explanation</em></strong>:</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The 40-percent evaluation is the greater when choosing between running evaluation, the minimum evaluation of 30 percent, and the facts.</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> does not apply to the decision to assign a 40-percent evaluation after the period of total disability because in doing so the claimant is never being paid less than the running 40-percent rate.  The rating is staging up to the 100-percent rate and prospectively down to that rate. </span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">However, the continuance of the 40-percent rate is contrary to the current facts.  The facts support only the minimum 30-percent evaluation and further reduction in evaluation would cause a reduction from the running 40 percent level.  Therefore, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> would apply and further reduction must be proposed.</span></span></span></div> </li> </ul> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/><br/><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">                                                                                                                          </span></span></span></div></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><strong><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">3<a id=\"3\" name=\"3\">.</a>  DCs That Provide for Indefinite Periods of Schedular Temporary Total Evaluation</span></span></strong></span></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span><br/> </p><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information on DCs that provide for indefinite periods of schedular temporary total evaluation, including</span></span></span></div> <ul> <li> <div><a href=\"#3a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">indefinite periods of schedular temporary total evaluation under a DC</span></span></span></a></div> </li> <li> <div><a href=\"#3b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">definition of indefinite periods of schedular temporary total evaluation</span></span></span></a></div> </li> <li> <div><a href=\"#3c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">prospective ratings under indefinite periods of schedular temporary total evaluation and 38 CFR 3.105(e)</span></span></span></a></div> </li> <li> <div><a href=\"#3d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">retrospective evaluations of indefinite periods of schedular temporary total evaluation and 38 CFR 3.105(e)</span></span></span></a></div> </li> <li> <div><a href=\"#3e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">cancer evaluations</span></span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">, and</span></span></div> </li> <li> <div><a href=\"#3f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">an example of a staged cancer evaluation</span></span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">.</span></span></div> </li> </ul> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; padding: 0px;\"> <h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Change Date</strong></span></span></span></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">August 3, 2020</span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.3.a<a id=\"3a\" name=\"3a\">.</a>  Indefinite Periods of Schedular Temporary Total Evaluation Under a DC</span></strong></span></span></span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The rating schedule prescribes temporary 100-percent evaluations under various DCs for indefinite periods of time following treatment (including hospitalization), surgery, or certain significant disease manifestations. </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on the interrelationship between schedular temporary total evaluations under a DC generally and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&amp;node=se38.1.4_129&amp;rgn=div8\" target=\"_blank\">38 CFR 4.29</a> or <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=e8efbac6c174a1f08121bc677943d397&amp;node=se38.1.4_130&amp;rgn=div8\" target=\"_blank\">38 CFR 4.30</a>, see <a href=\"#1b\" target=\"_self\">M21-1, Part VIII, Subpart iv, 8.D.1.b</a>.</span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.3.b<a id=\"3b\" name=\"3b\">.</a>  Definition: Indefinite Periods of Schedular Temporary Total Evaluation</span></strong></span></span></span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">A temporary 100-percent evaluation falls into the category <strong><em>indefinite periods of schedular temporary total evaluation</em></strong> when</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">the 100-percent criteria refers to an “indefinite” period or does not specify the period for which the total evaluation is permitted, <em>or</em></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">the end point for total disability is not known, therefore may not be set, at the time of rating. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Key features of DC provisions providing for indefinite periods of schedular temporary total evaluation also include</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">indication that current evidence of active disease or treatment will require a reexamination and reassessment of the disability level, and</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">a statement that reduction of the total disability is subject to the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a>. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Examples</em></strong>: </span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">A mandatory examination is conducted no sooner than one year following hospital discharge subsequent to kidney transplant surgery under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3d75649930f683e754ee2bb72720319a&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7531</a>.</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The period that the total disability will run may be a year or it may be longer, and the subsequent evaluation is dependent upon reexamination.</span></span></span></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">When the exam will be completed and what subsequent evaluation may be appropriate will not be known at the time of rating.</span></span></span></span></span></span></span></span></span></div> </li> </ul> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">An examination is to be conducted under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=3d75649930f683e754ee2bb72720319a&amp;mc=true&amp;node=se38.1.4_1115b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115b, DC 7528</a> no sooner than six months following the point at which a malignant neoplasm of the genitourinary system becomes inactive and there is no further antineoplastic treatment or therapy. </span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The period of total disability is not limited.</span></span></span></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Based on the need for evidence of inactivity, end of treatment, and review examination, the end point for total disability will not be known and set at the time of rating. </span></span></span></span></span></span></span></span></span></div> </li> </ul> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on assigning temporary total evaluations following receipt of a <em>Report of Hospitalization</em> at a VA hospital, see <a articleid=\"554400000177542\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 8, Section C - Convalescent Ratings Under 38 CFR 4.30\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177542/M21-1-Part-VIII-Subpart-iv-Chapter-8-Section-C-Convalescent-Ratings-Under-38-CFR-430\">M21-1, Part VIII, Subpart iv, 8.C</a>.</span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.3.c<a id=\"3c\" name=\"3c\">.</a>  Prospective Ratings Under Indefinite Periods of Schedular Temporary Total Evaluation and 38 CFR 3.105(e)</span></strong></span></span></span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> applies to reductions from the period of total disability specified in DCs providing for indefinite periods of schedular temporary total evaluation because these evaluations are most often awarded <em>prospectively</em> (total disability is still ongoing at the time of the rating). </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">At time of rating the decision maker will not know either one of the following:</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">the date that a future evaluation will replace the 100-percent rate, or</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">the level of evaluation that is appropriate to subsequently assign.  </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Therefore, the 100-percent evaluation is assigned as an open or running evaluation and later assignment of a lower evaluation after the indefinite period of schedular temporary total evaluation can result in a reduction or discontinuance of compensation payments being made.</span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">When preparing a rating decision prospectively establishing a temporary total evaluation for an indefinite period</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">enter the total disability from the effective date, and</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">assign a date for a future examination only if appropriate under <a articleid=\"554400000014321\" articlename=\"M21-1, Part IV, Subpart ii, Chapter 1, Section A - Determining the Need for Review Examinations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014321/M21-1-Part-IV-Subpart-ii-Chapter-1-Section-A-Determining-the-Need-for-Review-Examinations\">M21-1, Part IV, Subpart ii, 1.A</a> and the facts of record. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Later, when the period of total disability has ended, before assigning a lower evaluation</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">ensure that any examination report required by the DC is completed and considered, and</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">apply the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> when the rating will cause any reductions from the running total disability rate. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">consideration of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a>, see <a articleid=\"554400000177969\" articlename=\"M21-1, Part X, Subpart ii, Chapter 4, Section A - Rating Decisions for Reduction Due to Improvement\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177969/M21-1-Part-X-Subpart-ii-Chapter-4-Section-A-Rating-Decisions-for-Reduction-Due-to-Improvement\">M21-1, Part X, Subpart ii, 4.A</a></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">retrospective evaluations under DCs providing for indefinite periods of schedular temporary total evaluation, see <a href=\"#3d\" target=\"_self\">M21-1, Part VIII, Subpart iv, 8.D.3.d</a>, and</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">reducing staged ratings in original disability claims, see </span></span></span><a articleid=\"554400000014490\" articlename=\"Tatum v. Shinseki, Nov 3, 2010, 24 Vet.App. 139\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014490/Tatum-v-Shinseki-Nov-3-2010-24-VetApp-139\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>Tatum v. Shinseki</em></span></span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">, 24 Vet.App. 139 (2010).</span></span></span></div> </li> </ul> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.3.d<a id=\"3d\" name=\"3d\">.</a>  Retrospective Evaluations of Indefinite Periods of Schedular Temporary Total Evaluation and 38 CFR 3.105(e)</span></strong></span></span></span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">It is possible, in rare cases, that a temporary total evaluation under an indefinite period of schedular temporary total evaluation can be assigned retrospectively (when the period of total disability has already ended). </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">This can occur when a claim has a long duration or where the period of total disability was short. </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">In such cases the period of total disability and the subsequent disability level will be actually known at the time of rating.  Staging up to 100 percent and then down to the appropriate following level will not require application of the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> as long as there is not a reduction in compensation payments currently being made. </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Important</em></strong>:  If the total evaluation is reduced as part of a staged rating in the award for the original claim for such disability, then the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> do not apply.</span></span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.3.e<a id=\"3e\" name=\"3e\">.</a>  Cancer Evaluations</span></strong></span></span></span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Almost all cancers are evaluated using the same analysis.  See the table below for a description.</span></span></span></div> <div></div> <div> <table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 513px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a stage-description table.  Column 1 is the stage number, and column 2 provides a description of cancer evaluations.\" width=\"513\"> <thead> <tr> <th scope=\"col\" style=\"width: 11.8%; padding: 1px;\"> <div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Stage</strong></span></span></span></span></span></span></div> </th> <th scope=\"col\" style=\"width: 88.2%; padding: 1px;\"> <div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Description</strong></span></span></span></span></span></span></div> </th> </tr> </thead> <tbody> <tr> <td style=\"width: 11%; vertical-align: top; padding: 1px;\"> <div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">1</span></span></span></span></span></span></div> </td> <td style=\"width: 88.2%; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">A 100-percent evaluation is assigned for active cancer. This rating is typically assigned prospectively and can run indefinitely. If permanence is not conceded, schedule a review examination based on the evidence of record to ascertain continued status of active cancer or treatment.</span></span></span></span></span></span></div> </td> </tr> <tr> <td style=\"width: 11%; vertical-align: top; padding: 1px;\"> <div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">2</span></span></span></span></span></span></div> </td> <td style=\"width: 88.2%; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Evidence is submitted or obtained that there is no further surgical, x-ray, chemotherapy, or other qualifying antineoplastic treatment because the cancer is inactive. </span></span></span></span></span></span></div> </td> </tr> <tr> <td style=\"width: 11%; vertical-align: top; padding: 1px;\"> <div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">3</span></span></span></span></span></span></div> </td> <td style=\"width: 88.2%; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">When a cancer is being evaluated prospectively, such that the period of active symptoms is at or near the time of the analysis and associated decision making, VA schedules an examination <strong><em>no sooner than</em></strong> six months after discontinuance of the treatment or evidence of the cessation of active disease to determine whether there has been local recurrence or metastasis. </span></span></span></span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">In cases where the examination finds that the cancer is not active and/or does not require further treatment, the examination will also provide information for use in determining a rating based on residuals.</span></span></span></span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Notes</em></strong>: </span></span></span></span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Treatment records are insufficient to serve as the requirement for a VA examination.</span></span></span></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Where VA records exist, check the most current records in Compensation and Pension Records Interchange before ordering the examination to ensure that the cancer is no longer active and that the Veteran has not received antineoplastic treatment for at least six months.</span></span></span></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">For guidance on evaluating cancer retrospectively, refer to the exception in Step 4.</span></span></span></span></span></span></div> </li> </ul> </td> </tr> <tr> <td style=\"width: 11%; vertical-align: top; padding: 1px;\"> <div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">4</span></span></span></span></span></span></div> </td> <td style=\"width: 88.2%; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">VA takes rating action to reduce the total evaluation to an evaluation for residuals from an appropriate effective date based on the examination results and any other evidence of record.</span></span></span></span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Important</em></strong>:  Any change in evaluation shall be subject to the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> (requiring a proposed reduction, a 60-day opportunity to respond, and <em>prospective reduction</em> or discontinuance effective the last day of the month in which a 60-day period from the date of notice of the final rating action expires).</span></span></span></span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Exception</em></strong>:  As the court held in </span></span></span></span></span></span><a articleid=\"554400000014490\" articlename=\"Tatum v. Shinseki, Nov 3, 2010, 24 Vet.App. 139\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014490/Tatum-v-Shinseki-Nov-3-2010-24-VetApp-139\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>Tatum v. Shinseki</em></span></span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">, 24 Vet.App. 139 (2010), <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(e)</a> requirements are not applicable when the reduction is part of a staged rating assigned in the initial evaluation of the disability.  In that circumstance, once examination results or other medical evidence adequate for rating purposes showing residuals of the cancer are received, the total evaluation can be staged down on a facts-found basis to a date as early as six months after discontinuance of treatment – <em>even if that date was before the date of the examination, if needed, </em>subject to two important related principles:</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">the evidence must support the reduction on the date chosen, and</span></span></span></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">the facts-found date of reduction cannot take effect earlier than six months following cessation of treatment for the malignant neoplasm.</span></span></span></span></span></span></div> </li> </ul> </td> </tr> </tbody> </table> </div> <div> \t\t\t<div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on scheduling review examinations, see <a articleid=\"554400000014321\" articlename=\"M21-1, Part IV, Subpart ii, Chapter 1, Section A - Determining the Need for Review Examinations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014321/M21-1-Part-IV-Subpart-ii-Chapter-1-Section-A-Determining-the-Need-for-Review-Examinations\">M21-1, Part IV, Subpart ii, 1.A</a></span></span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"> and <a articleid=\"554400000014904\" articlename=\"M21-1, Part IV, Subpart ii, Chapter 1, Section B - Control of Future Examinations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014904/M21-1-Part-IV-Subpart-ii-Chapter-1-Section-B-Control-of-Future-Examinations\">B</a>.</span></span></span></div> </div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85.7pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iv.8.D.3.f<a id=\"3f\" name=\"3f\">.</a>  Example:  Staged Cancer Evaluation</span></strong></span></span></span></span></span></strong></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"> <p></p> </td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Facts</em></strong>:</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">An original claim for service connection for prostate cancer was received May 1, 2012. </span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">At that time there is active cancer.</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">A prostatectomy is performed on June 20, 2012. </span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Follow-up evaluations indicated that no antineoplastic treatment was needed.</span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">A VA examination was conducted June 6, 2013. </span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The examination confirmed that cancer had not recurred or metastasized.</span></span></span></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Exam findings were notable only for subjective reports of urinary frequency of daytime voiding interval between two and three hours. </span></span></span></span></span></span></span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The examiner reviewed treatment records of private urologist and oncologist and noted that the exam findings were consistent with findings from all private reports over the prior eight months (since October 2012). </span></span></span></span></span></span></span></span></span></span></span></span></div> </li> </ul> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">For this scenario, all evidence is reviewed for the original rating for the claimed prostate cancer. </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Result</em></strong>:</span></span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">Award a 100-percent evaluation from the date of claim. </span></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The reduced evaluation is warranted December 20, 2012, six months after cessation of treatment for a malignant neoplasm.  </span></span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Explanation</em></strong>:</span></span></span></div> <ul> <li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The VA exam supports that the cancer did not recur at any time after June 20, 2012, and the disability shown since October 2012 was consistent with a 10-percent evaluation. </span></span></span></li> <li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">However, October 2012 is not at least six months after the end of antineoplastic treatment.  The earliest date that the 100-percent evaluation can be staged down is December 20, 2012.</span></span></span></li> <li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial , helvetica , sans-serif\">The effective day of payment for the 10-percent evaluation is January 1, 2013.  Such action is consistent with standard practices and eliminates technical issues regarding establishment of a payment period prior to the end of the month.  </span></span></span></li> </ul> </td> </tr> </tbody></table><div class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></div><p style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177542\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 8, Section C - Convalescent Ratings Under 38 CFR 4.30\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177542/M21-1-Part-VIII-Subpart-iv-Chapter-8-Section-C-Convalescent-Ratings-Under-38-CFR-430\">&lt;-- Previous Section</a> <a articleid=\"554400000177488\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 9, Section A - Claims Based on Participation in Special Operations Incidents\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177488/M21-1-Part-VIII-Subpart-iv-Chapter-9-Section-A-Claims-Based-on-Participation-in-Special-Operations-Incidents\">Next Section --&gt;</a></span></span></p><p style=\"text-align: left\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 11px\"><a href=\"#top\" target=\"_self\">To Top</a></span></span></p></div><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=0492397295b1bf21b63311e89f43cb5c&mc=true&node=se38.1.3_1951&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&node=se38.1.4_1104&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&node=se38.1.4_129&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=2a89050ff6cf08e7dad77e1d39e8950c&node=se38.1.4_130&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=3d75649930f683e754ee2bb72720319a&mc=true&node=se38.1.4_1115b&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=3d75649930f683e754ee2bb72720319a&mc=true&node=se38.1.4_171a&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=6df760a2ba821e0c11058145aee4e2fa&mc=true&node=se38.1.3_1327&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=814b9180da916bc488138110ab478909&node=se38.1.4_129&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=814b9180da916bc488138110ab478909&node=se38.1.4_130&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=9aedef38b71a775fb25e47eb84124eaa&mc=true&node=se38.1.3_1327&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=dd9917e4ca832b29e6399122c1083675&node=se38.1.3_1105&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=e8efbac6c174a1f08121bc677943d397&node=se38.1.4_1104&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=e8efbac6c174a1f08121bc677943d397&node=se38.1.4_130&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=e8efbac6c174a1f08121bc677943d397&node=se38.1.4_171a&rgn=div8"
  ],
  "scraped_at": "2025-06-16T23:04:29.963626",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177488/M21-1-Part-VIII-Subpart-iv-Chapter-9-Section-A-Claims-Based-on-Participation-in-Special-Operations-Incidents"
}